07:00 , Mar 24, 2014 |  BioCentury  |  Strategy

A Remembrance: The quintessential serial entrepreneur

Very few of us will live as long, invent as much, or improve as many lives as Alejandro Zaffaroni. Alex, who was 91 when he passed away this month, already was an eminence grise in the...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Company News

Affymetrix board of directors update

Affymetrix Inc. (NASDAQ:AFFX), Santa Clara, Calif.   Business: Microarrays   Deceased: Alejandro Zaffaroni, a founder, at the age of 91; he also founded Alexza Pharmaceuticals Inc.; and Alza Corp., which Johnson & Johnson acquired...
02:20 , Mar 7, 2014 |  BC Extra  |  Company News

Zaffaroni passes away

Life science entrepreneur Alejandro Zaffaroni passed away on March 1 at the age of 91. Zaffaroni founded a number of companies, including Affymetrix Inc. (NASDAQ:AFFX); Alexza Pharmaceuticals Inc. (NASDAQ:ALXA); and Alza Corp., which Johnson &...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Maxygen management update

Maxygen Inc., Santa Clara, Calif.   Business: Enabling technology   Hired: Alejandro Zaffaroni, Ph.D., as CEO, currently a director at Affymax Research Institute (Palo Alto, Calif.); Russell Howard, Ph.D., as president and COO; formerly president and scientific...
07:00 , Oct 23, 2006 |  BioCentury  |  Strategy

Eidogen-Sertanty Inc.

Eidogen-Sertanty Inc. Eidogen-Sertanty Inc. San Diego, Calif. Technology: Informatics software, DirectDesign computational drug discovery technology Disease focus: NA Clinical status: NA Founded: 2005 from the merger of Eidogen Inc. and Sertanty Inc. University collaborators:...
08:00 , Jan 2, 2006 |  BioCentury  |  Finance

Profiling Perlegen's money

Profiling Perlegen's money Profiling Perlegen's money Perlegen has raised $207 million in private financings, but less than 15% has come from traditional VCs. The private rounds exclude the $50 million that Pfizer (PFE) invested last...
08:00 , Jan 2, 2006 |  BioCentury  |  Finance

Ebb & Flow

Perlegen is remaining mum on when and if it will test the IPO waters, but there's a clear incentive for the company to join the public space this year. That's because the personalized medicine and...
08:00 , Jan 10, 2005 |  BioCentury  |  Finance

Ebb & Flow

Last week saw two series D rounds go in opposite directions. Cancer play Nereus opted for a two-part financing, and maintains that having milestone-contingent money is important for discipline. On the flip side, drug delivery...
08:00 , Jan 6, 2005 |  BC Extra  |  Financial News

Alexza raises $52 million

Drug delivery company Alexza (Palo Alto, Calif.) raised $52 million in a series D round co-led by Alloy and Delphi. New investors Abingworth; MDS Capital; Pacific Rim; T. Rowe Price; and WestRiver joined existing investors...
08:00 , Mar 15, 2004 |  BioCentury  |  Finance

'A' for effort

'A' for effort Company Raised Date Focus Country Investors Pedigree Biovitrum $85.0 8/1/01 Metabolic Sweden MPM Capital; Nordic Capital; Karolinska Investment Fund; ABN AMRO; Carnegie Asset Management; H&B Capital; Next Gear Spun...